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use of RTB after adjuvant breast radiotherapy was 38% in Era 1, 
29% in Era 2 and 76% in Era 3 (p < 0.001). Ten-year LRFS was 
85.3% in Era 1, 93.9% in Era 2 and 91.9% in Era 3. On MVA there 
was a significant decrease in relapse going from Era 1 (pre-HT, 
pre-boost) to Era 2 (HT, no boost) (HR 2.2, p = 0.03), but no 
change in relapse from Era 2 (HT, no boost) to Era 3 (HT and 
boost) (HR 1.0, p = 0.97). For LRFS across all three eras, there 
was no significant difference for patients that received a boost 
(92.9%) and those that did not (88.6%, p = 0.31) but there was a 
significant improvement for ER-positive patients that received 
HT (91.8% versus 81.6%, p = 0.01).  
Conclusions: This study showed that new breast cancer 
therapies were adopted swiftly in response to new clinical 
practice guidelines. The introduction of HT was associated with 
an 8.6% improvement in ten-year LRFS. However, for a 
population of patients that was routinely prescribed HT, no 
improvement in LRFS was observed with the addition of routine 
RTB. RTB causes toxicity and offers no survival benefit; its 
routine use should be re-evaluated in the HT era.  
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Purpose: To determine whether DIBH produced a clinically 
meaningful reduction in pulmonary dose in comparison to free 
breathing (FB) during adjuvant locoregional radiation (RT) for 
right-sided breast cancer. 
Methods and Materials: Thirty women with Stages 0-I left-sided 
breast cancer and who had both DIBH and FB CT scans as part of 
standard care were included. The right-sided IMC nodes were 
contoured according to ESTRO guidelines on DIBH and FB scans, 
with care taken to ensure comparability between scans. A four-
field, modified-wide tangent RT plan was developed on each 
scan to include the right breast and full regional nodes, including 
a minimum dose of 80% to the IMC volume. The junction between 
the supraclavicular and tangent fields was at the inferior extent 
of the ossified medial clavicle. Treatment plans were calculated 
in Eclipse using the Acuros algorithm version 11. FB and DIBH plan 
metrics were compared using Wilcoxon-signed rank testing. 
Results: IMC coverage was equivalent between DIBH and FB 
plans; V80 was 100% on both plans and D100 was 39.2 and 39.5 
Gy for DIBH and FB, respectively. Twenty-one patients (70%) had 
≥ 5% reduction in ipsilateral lung V20 with DIBH compared to FB. 
The average ipsilateral lung V20 decreased by 7.8% (range: 0 to 
20%; p < 0.001) and the mean lung dose decreased by 3.4 Gy with 
DIBH (range: -0.2 to 9.1; p < 0.001). The right lung absolute V20 
Gy gain from DIBH was larger among 15 patients with the highest 
V20 compared to 15 patients with the lowest V20 on FB (10.1% 
versus 5.6% respectively; p = 0.01). There was a mean reduction 
of 42.3 cc (range: 0 to 178.9; p < 0.001) in the volume of liver 
receiving 50% of the prescription dose. The differences in mean 
heart doses were statistically significant, but not likely clinically 
significant: MHD was 0.88 Gy (range: 0.67 to 1.27) and 1.00 Gy 
(range: 0.75 to 1.48) (p < 0.001) for DIBH and FB, respectively.  
Conclusions: DIBH reduced mean ipsilateral lung V20 by 7.8% and 
mean lung dose by 3.4 Gy. For some patients, the volume of liver 
receiving ≥ 25 Gy can also be reduced with DIBH. DIBH should be 
available as a treatment strategy to reduce right lung V20 
without compromising IMC or supraclavicular nodal coverage for 
patients with right-sided breast cancer during locoregional RT. 
This strategy can be advantageous in cases where the ipsilateral 
V20 on FB approaches 30%, a value that prompts many radiation 
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Purpose: Randomized clinical trials have shown equivalent local 
control for patients with early-stage breast cancer (BC) treated 
with conventional fractionation (CF) or hypofractionated (HF) 
adjuvant whole breast radiotherapy (WBRT). However, women 
less than 50 years of age have been underrepresented in these 
trials, and controversy still remains in relation to optimal 
fractionation schedule in this patient group. Our institutional 
policy allows for both schedules, therefore we compared local 
control in young women following breast-conserving surgery 
(BCS), and identified factors associated with recommendation of 
CF or HF schedule. 
Methods and Materials: Two hundred and seventy-one women 
under 50 years of age with early-stage invasive BC (pT1-T2, pN0) 
treated from September 2009 to December 2013 were identified 
from an institutional database. BCS was followed by adjuvant CF 
(50 Gy in 25 fractions) or HF (40 or 42.4 Gy in 16 fractions) WBRT, 
followed by a boost to the tumour bed of 10-16 Gy in in 5-8 
fractions. Data on tumour characteristics and adjuvant systemic 
therapies were collected. Length of follow up was calculated 
from the completion date of radiotherapy (RT) to the date of 
most recent imaging or clinical review in which disease status 
was recorded. 
Results: Two hundred and twenty-seven (83.8%) patients were 
treated with HF and 44 (16.2%) with CF WBRT. Median follow up 
was 2.9 years (range 0-5.8 years) and median age was 42.8 years 
(range 19-49 years). Most patients had invasive ductal carcinoma 
(94%), unifocal (86%), Grade 1 or 2 (65%) and ER positive (88%) 
disease, of which 81% received adjuvant endocrine therapy. 
Lymphovascular invasion was associated in 16%, 54% received 
adjuvant systemic chemotherapy, 14% had HER2-positive disease 
and 8.5% of cases were triple negative (TN). Local control was 
achieved in 225 (99.1%) and 43 (97.7%) patients in the HF and CF 
groups, respectively. The mean age (± standard deviation) of 
patients receiving HF was 43.5 ± 4.5 years, and 39.3 ± 7.5 years 
for the CF group (p < 0.01). On univariate analysis, age greater 
than 40 years was associated with a higher likelihood of receiving 
HF WBRT (OR = 2.52, 95% CI 1.32-4.87), and patients with TN 
disease were 67% more likely to receive CF WBRT (OR = 0.33, 95% 
CI 0.13-0.87). No other differences were identified between the 
CF and HF groups, including receipt of systemic therapies. 
Conclusions: Young women with early-stage BC treated with HF 
WBRT following BCS obtained excellent local control that was 
comparable to CF WBRT. At our institution, HF was more likely 
to be recommended for women over 40 years of age or for non-
TN BC in this patient population. HF WBRT shortens total 
treatment time, is more convenient for patients and may be 
considered for women less than 50 years of age. 
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Purpose: Recent literature has suggested that higher volumes of 
practice are associated with better survival outcomes for head 
and neck cancer (HNC) patients. Some limitations in these 
studies, however, include looking at the volume of practice on a 
cancer centre level, not a provider level, and not controlling for 
rurality of patient residence. The primary objective of this study 
was to evaluate the effect of treatment centre on the overall 
survival (OS) and cancer-specific survival (CSS) of HNC patients 
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in British Columbia (BC), while controlling for physician case 
volume and rurality of patient residence. 
Methods and Materials: The BC Cancer Registry (BCCR), a 
population-based provincial database, was used to identify all 
patients in BC diagnosed for the first time with a primary non-
thyroid HNC and treated with radiotherapy between 2006 and 
2011. Patient demographics, pathology, stage, treatments, and 
death data were abstracted. Chart review of all patients was 
performed using the British Columbia Cancer Agency Information 
System (CAIS). Patients were categorized as residing in large, 
small and rural local health authorities (LHAs) using BC Stats and 
BC Ministry of Health information. Physician case frequency was 
defined as low (0-14 cases per year), medium (15-29 cases per 
year) and high (> 30 cases per year). We hypothesized that 
survival would not significantly differ among BC cancer centres 
after controlling for rurality, physician case frequency, IMRT use, 
and other patient and tumour characteristics. 
Results: 2330 HNC patients were included in our study. The five-
year head and neck CSS (HNCSS) for the Abbotsford, Fraser 
Valley, Southern Interior, Vancouver and Vancouver Island 
centres was 72%, 71%, 73%, 75% and 68%, respectively (p = 0.54), 
while OS was 59%, 60%, 60%, 65% and 56%, respectively (p = 0.06). 
On multivariable analysis, after controlling for age, gender, 
cancer stage, anatomical site, treatment and physician case 
frequency, neither HNCSS (HR range = 0.92-1.03; p = 0.57-0.91) 
nor OS (HR range = 0.93-1.07; p = 0.47-0.92) was significantly 
different by treatment centre. OS was also not significantly 
different for patients treated by physicians with low case 
frequency (HR = 0.96; 0.77-1.19; p = 0.72) and middle case 
frequency (HR = 1.01; 0.83-1.23; p = 0.91) in reference to high 
case frequency. There was no significant difference in OS among 
patients living in rural LHAs (HR = 0.97; 0.85-1.11; p = 0.67) and 
small LHAs (HR = 1.13; 0.86-1.47; p = 0.38) in reference to large 
LHAs. 
Conclusions: There was no significant difference in survival 
among British Columbia Cancer Agency treatment centres after 
controlling for differences in rurality, physician case volume and 
other potential confounding variables. 
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Purpose: Lymph node density (LND, number of positive lymph 
nodes/total number of excised lymph nodes) has been shown to 
be associated with outcomes in multiple malignancies. In this 
study, the impact of LND on distant metastasis (DM) and overall 
survival (OS) in oral cavity squamous cell carcinoma (OSCC) was 
investigated. 
Methods and Materials: Retrospective review of pN0-2 OSCC 
patients treated between 1994-2012 with curative surgery with 
neck dissection (ND) +/- post-operative radiotherapy (PORT) with 
or without concurrent chemotherapy (CCT). LND was subjected 
to multivariable analysis (MVA) of DM and OS, adjusted for pT3-
4 category, extracapsular extension (ECE), high histological 
Grade (G3), lymphovascular invasion (LVI), perineural invasion 
(PNI), and tumour subsite. 
Results: Overall 914 patients were identified; median age: 61 
years (18-92); median follow up: 51 months (1–189); pT3-4: 283 
(31%); pN-classification: N0: 482 (53%), N1: 128 (14%), N2a: 6 
(0.5%); N2b: 225 (24.5%); N2c: 73 (8%); median number of 
dissected nodes: 36 (6-125); median number of pN+: 2 (1-49); 
median LND for pN+ patients: 0.06; ECE: 187 (20%); G3: 147 
(16%); LVI: 115 (13%); PNI: 416 (46%). Bilateral ND was performed 
in 367 (40%); PORT was used in 452 (49%); and CCT in 80 (9%). 
The five-year distant control (DC) and OS were 89% and 70%; 
respectively. pT3-4 (p < 0.001), G3 (p < 0.001), LVI (p = 0.0013), 
and PNI (p < 0.001) were all associated with high LND. On MVA, 
LND > 0.06 was associated with more DM (HR = 1.8; 95%CI = 1.1-
3.1; p = 0.017) and lower OS (HR = 2; 95%CI = 1.4–2.8; p < 0.001). 
In subgroup analysis of pN2 patients (n = 304): higher LND (> 0.14) 
was associated with lower five-year DC (67%, p = 0.014) and OS 
(25%, p < 0.001), and on MVA within the pN2 subgroup, both 
higher LND (p < 0.001) and ECE (p = 0.006) were associated with 
lower OS. 
Conclusions: High LND is associated with higher rate of DM and 
lower OS in OSCC. LND should be assessed in pN2 patients in 
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Purpose: Modern radiation therapy (RT) techniques offer precise 
delivery to the defined targets in head and neck cancer (HNC) 
while respecting surrounding critical organ tolerances. This is 
due in part to the enhanced ability to define the gross tumour 
volume (GTV) with supplemental imaging such as MRI and PET 
scans. As a standard, a high dose clinical target volume (CTV) of 
5 mm is added to the GTV to further ensure complete coverage 
of gross disease. However, HN tumours often shrink during RT, 
which suggests that the high dose CTV margin during treatment 
may be greater than the original 5 mm, thus leading to 
overdosage of normal tissues. This study intends to quantify the 
potential gain of an adaptive technique that maintains the CTV 
to a changing gross tumour volumes in a series of HNC patients 
treated with chemoradiotherapy. 
Methods and Materials: A prospective study in 2009 enrolled 
advanced HNC patients undergoing curative IMRT to receive a 
dynamic pre-treatment FDG PET-CT simulator scan, which was 
also repeated intratreatment (IT) between the 10th and 15th 
fraction. Fifty-two patients were evaluated. Two radiation 
oncologists separately contoured GTVs in the pre- and IT scans 
to account for inter-observer variability. Rigid fusion of the 
planning CT to pre- and IT PET-CT scans was performed. Margin 
expansions ranging from 1-25 mm were performed on the pre-
treatment GTV to volumetrically match the original CTV (as 
defined by the treating radiation oncologist), based on optimal 
Dice Similarity Indices (DSI). An identical process took place with 
the IT PET CT scan, where the IT GTV margins were expanded to 
the original treatment CTV. 
Results: Fifty-two patients were evaluated with a total of 152 
targets (50 primaries and 102 LNs). Volume matching given by 
DSI showed that the pre-treatment GTV needed an average 7.22 
± 4.75 mm expansion to optimally match the clinical CTV while 
the IT GTV required a margin of 8.27 ± 4.18 mm. On average, the 
radial size of the primary CTV decreased by 1.05 ± 3.59 mm 
between pre- and IT scans but 17 patients (32.7%) had a 
shrinkage over 5 mm and six patients (11.5%) had tumour growth 
of more than 5 mm. Nineteen patients had a paradoxical 
response between the primary and the LNs. On multivariate 
analysis, after controlling for smoking history, HPV status and 
stage, non-smokers only showed significant shrinkage in both 
primaries (mean = 2.34 ± 0.64, p = 0.0004) and LNs (mean = 2.521 
± 0.92, p = 0.008). In total, primaries and LNs had similar 
outcome with a mean of 1.14 ± 3.99 mm and 0.67 ± 3.63 mm 
respectively (p = 0.54). 
Conclusions: Our results show that HNC tumour shrinkage during 
RT is highly variable. A subset of patients is highly responsive to 
treatment where an adaptive approach to reduce treatment 
margins (CTV) may reduce normal tissue toxicities. Non-smokers 
respond better than smokers while HPV-positive patients don’t 
seem to have an early response at two to three weeks. 
 
